20 terminated. 20 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Terminated 20 |
| Phase 1 | 9 | Terminated 9 |
Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies MGTA-145, Plerixafor - Related Donors Donating PBSC to a Family Member, Healthy Donors | Phase 2 | Terminated | Ensoma | 7 | 2021-06-16 | 2024-11-06 |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Infusion of Treg - Acute Lymphoblastic Leukemia, Burkitt Lymphoma | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2017-02-16 | 2020-09-29 |
| Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) Ciprofloxacin 750 MG, Etoposide, Ciprofloxacin 1000 MG - Leukemia, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | University of Florida | 11 | 2016-12-16 | 2022-08-05 |
| Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS allogeneic, donor-derived NK cells - Acute Myelogenous Leukemia | Phase 2 | Terminated | Asan Medical Center | 77 | 2015-06-01 | 2019-07-08 |
| Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) TAK-659 - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 43 | 2015-03-09 | 2023-02-08 |
| Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome PD-616 - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | Biosuccess Biotech Co., Ltd. | 13 | 2013-01-01 | 2018-07-24 |
| Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies CliniMACS® CD34 Reagent System, Fludarabine, Melphalan - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Weill Medical College of Cornell University | 2 | 2012-10-26 | 2018-07-11 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY) - Hematologic Malignancy, Leukemia | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 4 | 2012-03-01 | 2025-05-04 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match Busulfan, Clofarabine, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Terminated | Texas Oncology Cancer Center | 1 | 2011-11-01 | 2013-11-25 |
| A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia Birinapant - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | Abramson Cancer Center at Penn Medicine | 27 | 2011-11-01 | 2021-06-24 |
| T-Cell Depleted Double UCB for Refractory AML Allopurinol, Fludarabine, Total body irradiation - Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 3 | 2011-10-01 | 2017-12-28 |
| Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years Clofarabine, Cytarabine - Acute Myelogenous Leukemia | Phase 2 | Terminated | PETHEMA Foundation | 75 | 2010-09-01 | 2014-04-07 |
| Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) Plerixafor, Clofarabine - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 22 | 2010-08-01 | 2019-08-28 |
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) lenalidomide - Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 2 | Terminated | Technische Universität Dresden | 10 | 2008-04-01 | 2013-09-27 |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) Campath, Busulfan, Fludarabine - Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 4 | 2007-06-01 | 2016-05-04 |
| Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia Interleukin-2 - Acute Myelogenous Leukemia | Phase 2 | Terminated | Leo W. Jenkins Cancer Center | 18 | 2006-07-01 | 2019-09-12 |
| Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) Troxatyl™ (Cytotoxic Chemotherapeutic) - Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | SGX Pharmaceuticals, Inc. | 50 | 2003-04-01 | 2008-01-17 |
| Study of Gelonin Purging of Autologous Stem Cells for Transplantation Gelonin, Busulfan, Fludarabine - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2002-07-01 | 2018-10-31 |
| Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia Arsenic Trioxide (ATO), Ascorbic Acid - Acute Myelogenous Leukemia | Phase 2 | Terminated | University of Southern California | 11 | 2002-04-01 | 2014-07-25 |
Leukemia, Myeloid, Acute (20) · Myelodysplastic Syndromes (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia (5) · Hodgkin Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Neoplasms, Plasma Cell (2) · Anemia, Aplastic (1) · Anemia, Refractory, with Excess of Blasts (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1)
Hemic and Lymphatic Diseases (20) · Leukemia, Myeloid (20) · Neoplasms (20) · Neoplasms by Histologic Type (20) · Hematologic Diseases (19) · Leukemia (15) · Bone Marrow Diseases (9) · Immune System Diseases (7) · Immunoproliferative Disorders (6) · Leukemia, Lymphoid (6) · Lymphatic Diseases (6) · Disease Attributes (5) · Lymphoproliferative Disorders (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
fludarabine (5) · Busulfan (4) · Clofarabine (3) · Cyclophosphamide (2) · Cytarabine (2) · Etoposide (2) · Interleukin-2 (2) · Melphalan (2) · Stem Cell Transplantation (2) · Tacrolimus (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · plerixafor (2) · Alemtuzumab (1) · Allopurinol (1)
M.D. Anderson Cancer Center (2) · Masonic Cancer Center, University of Minnesota (2) · Abramson Cancer Center at Penn Medicine (1) · Asan Medical Center (1) · Baylor College of Medicine (1) · Biosuccess Biotech Co., Ltd. (1) · Calithera Biosciences, Inc (1) · Ensoma (1) · GT Biopharma, Inc. (1) · Leo W. Jenkins Cancer Center (1) · PETHEMA Foundation (1) · SGX Pharmaceuticals, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Technische Universität Dresden (1) · Texas Oncology Cancer Center (1)
United States (17) · Canada (1) · Germany (1) · South Korea (1) · Spain (1)
Anthony S Stein, MD (1) · Claudio Brunstein, MD, PhD (1) · Dan Douer, MD (1) · Dianna S. Howard, M.D. (1) · Dolores Grosso, DNP, CRNP (1) · Jan A. Burger, MD (1) · Koen van Besien, MD, PhD (1) · Mark B Juckett, MD (1) · Michael Verneris, M.D. (1) · Neal Flomenberg, MD (1) · Noelle Frey, MD (1) · Paul Walker, MD (1) · Rammurti T Kamble, MD (1) · Randall Brown, MD (1) · Seah Lim, MD (1)